TytoCare's AI Respiratory Suite Recognized on TIME's 2025 Best Inventions List

NEW YORK, Oct. 14, 2025 /PRNewswire/ -- TIME has honored TytoCare by listing the company's AI Respiratory Suite among its Best Inventions of 2025, underscoring TytoCare's leadership in driving the future of AI in healthcare with FDA-approved technologies.

"Being recognized by TIME underscores the significance of the work we have done at TytoCare to build our Tyto Insights Lung Sounds Suite," said Dedi Gilad, CEO and Co-Founder of TytoCare. "Our database of lung sounds is the biggest in the world, and it has enabled us to build algorithms that recognize wheezes, crackles, and rhonchi, leading to our three FDA clearances. We empower clinicians at any level to diagnose and support their patients in ways that only specialists could previously have done, helping patients access care and easing the pressures facing clinicians across the world.

TytoCare, a virtual care company enabling accessible, high-quality primary care from home, is the first company in the world to receive FDA clearance for AI-based detection of all three major abnormal lung sounds. The company recently completed its AI-powered Lung Sound Suite with the FDA clearance of Tyto Insights™ for Rhonchi, Wheeze, and Crackle Detection. TytoCare's platform offers comprehensive, AI-driven analysis of the three most clinically significant abnormal lung sounds directly within its Home Smart Clinic and Pro Smart Clinic solutions. Diagnosing these abnormal lung sounds presents a recognized challenge even for trained medical professionals, as noted in the FDA clearance, underscoring the significance of this advancement as a major milestone in the evolution of virtual care. 

Tyto Insights^TM Lung Sounds Suite is built on TytoCare's proprietary database of 1.8 million lung sound recordings and leverages machine-learning algorithms trained and validated by pulmonologists. Each component of the suite: wheeze detection (FDA-cleared in 2023), crackle detection (FDA-cleared in 2024), and rhonchi detection (FDA-cleared in 2025),  analyzes lung acoustic signals in real-time and flags potential abnormalities for clinical review.

Clinical validation demonstrated that the device performs equivalently to, or better than, non-pulmonologist clinicians, confirming that the algorithm is a powerful and reliable diagnostic tool. The algorithm showed strong discriminative ability across all three sound types, as measured by the area under the receiver operating characteristic curve (AUC). The algorithm's AUC was 95.85%, compared to 79.45% for general practitioners and 83.03% for experts. Respiratory conditions account for more than 40% of diagnoses made using TytoCare's platform, underscoring the importance of intelligent respiratory diagnostics in home-based care. 

TIME's annual list recognizes products, software and services that are solving compelling problems in creative ways. TytoCare's technology was recognised as a special mention.

About TytoCare  

TytoCare, recently named one of the Top HealthTech Companies by TIME,  is a virtual healthcare company that enables leading health plans and providers to deliver remote healthcare to the whole family through its Home Smart Clinic. The Home Smart Clinic enables the whole family to conduct remote physical exams with a doctor, replicating in-clinic exams for immediate answers from home. TytoCare drives utilization rates that are five times higher than traditional telehealth services; reduces the total cost of care by an average of five percent; diverts ED visits by an average of 10.8 percent; and has a high average NPS of 83. To complete its offering, TytoCare also provides the Pro Smart Clinic, for professional settings outside the home to serve rural clinics, schools, workplaces, and more. TytoCare serves over 250 major health systems and health plans in the U.S., Europe, Asia, Latin America, and the Middle East.      

Contact:

Mira Marcus
TytoCare PR 
[email protected]

SOURCE TytoCare